Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220161 · ClinicalTrials.gov registry record · NA
Trigeminal Nerve Stimulation of the Treatment of Epilepsy
A NA study of Epilepsy (Treatment Refractory), sponsored by Baylor College of Medicine.
- Active
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07220161: Active NA study of Epilepsy (Treatment Refractory), sponsored by Baylor College of Medicine.
NCT07220161 is a NA study of Epilepsy (Treatment Refractory) that is active but no longer recruiting, run by Baylor College of Medicine. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220161, a NA study of Epilepsy (Treatment Refractory), is active but no longer recruiting, sponsored by Baylor College of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Epilepsy is a common neurological disorder among veterans. Medications do not control seizures in 1/3rd of patients, who often require neurostimulation. However, current neurostimulation devices are invasive. Objective: The investigators propose a novel clinical trial to repurpose the FDA-approved Cefaly device, designed for migraine relief, to treat epilepsy. The Cefaly device works by non-invasive Trigeminal neurostimulation (TNS). TNS has previously shown promising preliminary results in seizure improvement. Design: The investigators will engage 24 veterans with drug-resistant epilepsy, half of whom will receive standard care, while the other half will receive standard care plus Cefaly. This will be followed by a crossover of the treatment/control groups. The primary objective is to evaluate seizure frequency improvement over 12 months.
Primary Outcome
The primary outcome will be the reduction in seizure frequency with the treatment device compared to baseline measurements.
Conditions Studied
Interventions
- DEVICE Trigeminal nerve stimulation
Study Locations (1)
Texas
- Debakey VA Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What the registry record for NCT07220161 still lists
NCT07220161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Epilepsy (Treatment Refractory) appearing as the primary indexed condition, and to 1 intervention - of which Trigeminal nerve stimulation is the first listed.
NCT07220161 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07220161 about?
NCT07220161 is a clinical study titled "Trigeminal Nerve Stimulation of the Treatment of Epilepsy". Background: Epilepsy is a common neurological disorder among veterans. Medications do not control seizures in 1/3rd of patients, who often require neurostimulation. However, current neurostimulation devices are invasive. Objective: The investigators propose a novel clinical trial to repurpose the FD...
What is the current status of trial NCT07220161?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2025-05-08. Estimated completion is 2026-06-30.
What conditions does trial NCT07220161 study?
This clinical trial studies the following conditions: Epilepsy (Treatment Refractory).
What interventions are being tested in trial NCT07220161?
The interventions under investigation include: Trigeminal nerve stimulation (DEVICE).
Who is sponsoring clinical trial NCT07220161?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220161 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy (Treatment Refractory)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07220161's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI